Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2005 1
2006 1
2007 6
2008 10
2009 44
2010 53
2011 63
2012 77
2013 97
2014 150
2015 141
2016 174
2017 179
2018 199
2019 176
2020 199
2021 158
2022 131
2023 133
2024 106
2025 37

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,812 results

Results by year

Filters applied: . Clear all
Page 1
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Panés J; VEGA Study Group. Feagan BG, et al. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1. Lancet Gastroenterol Hepatol. 2023. PMID: 36738762 Clinical Trial.
Patients were randomly assigned (1:1:1) using a computer-generated randomisation schedule to combination therapy (subcutaneous golimumab 200 mg at week 0, subcutaneous golimumab 100 mg at weeks 2, 6, and 10, and intravenous guselkumab 200 mg at weeks 0, 4, and 8, fo …
Patients were randomly assigned (1:1:1) using a computer-generated randomisation schedule to combination therapy (subcutaneous golimumab …
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P; PURSUIT-Maintenance Study Group. Sandborn WJ, et al. Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010. Epub 2013 Jun 14. Gastroenterology. 2014. PMID: 23770005 Clinical Trial.
Patients who responded to induction therapy with golimumab (n = 464) were assigned randomly to groups given placebo or injections of 50 or 100 mg golimumab every 4 weeks through week 52. ...Among all patients given golimumab in the study, 3 died (from sepsis, …
Patients who responded to induction therapy with golimumab (n = 464) were assigned randomly to groups given placebo or injections of …
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P; PURSUIT-SC Study Group. Sandborn WJ, et al. Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5. doi: 10.1053/j.gastro.2013.05.048. Epub 2013 Jun 2. Gastroenterology. 2014. PMID: 23735746 Clinical Trial.
We evaluated subcutaneous golimumab induction therapy in TNF-alpha antagonist-naive patients with moderate-to-severe UC despite conventional treatment. ...Rates of clinical remission and mucosal healing and mean changes in IBDQ scores were significantly greater in both …
We evaluated subcutaneous golimumab induction therapy in TNF-alpha antagonist-naive patients with moderate-to-severe UC despite conve …
Golimumab.
Mazumdar S, Greenwald D. Mazumdar S, et al. MAbs. 2009 Sep-Oct;1(5):422-31. doi: 10.4161/mabs.1.5.9286. Epub 2009 Sep 15. MAbs. 2009. PMID: 20065639 Free PMC article. Review.
Golimumab, a human anti-TNFalpha IgG1kappa monoclonal antibody, was approved in the US and Canada in April 2009 as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and is undergoing regulatory review in the EU for these indications. The …
Golimumab, a human anti-TNFalpha IgG1kappa monoclonal antibody, was approved in the US and Canada in April 2009 as a treatment for rh …
Golimumab-Associated Glomerulonephritis.
Agrawal N, Roy N, Naramala S, Konala VM, Adapa S, Dhingra H, Aronow WS. Agrawal N, et al. Am J Ther. 2021 Jan-Feb 01;28(1):e145-e147. doi: 10.1097/MJT.0000000000000946. Am J Ther. 2021. PMID: 33369915 No abstract available.
Golimumab for the treatment of axial spondyloarthritis.
Palazzi C, D'angelo S, Gilio M, Leccese P, Padula A, Olivieri I. Palazzi C, et al. Expert Opin Biol Ther. 2017 Jan;17(1):129-133. doi: 10.1080/14712598.2017.1256387. Epub 2016 Nov 9. Expert Opin Biol Ther. 2017. PMID: 27817204 Review.
In the field of axial spondyloarthritis, golimumab, a fully human monoclonal anti-TNFalpha administered subcutaneously every 4 weeks, has shown significant efficacy and good safety in patients with ankylosing spondylitis. ...Preliminary data concerning an open-label extens …
In the field of axial spondyloarthritis, golimumab, a fully human monoclonal anti-TNFalpha administered subcutaneously every 4 weeks, …
Golimumab (anti-TNF monoclonal antibody): where we stand today.
Melo AT, Campanilho-Marques R, Fonseca JE. Melo AT, et al. Hum Vaccin Immunother. 2021 Jun 3;17(6):1586-1598. doi: 10.1080/21645515.2020.1836919. Epub 2020 Dec 28. Hum Vaccin Immunother. 2021. PMID: 33369527 Free PMC article. Review.
Biological therapies, like TNF inhibitors, have been revolutionizing the course of these disorders. Golimumab is a transgenic anti-TNF monoclonal antibody that acts primarily by targeting and neutralizing TNF, thus preventing inflammation. ...This review charts the clinica …
Biological therapies, like TNF inhibitors, have been revolutionizing the course of these disorders. Golimumab is a transgenic anti-TN …
Golimumab: A Review in Inflammatory Arthritis.
Frampton JE. Frampton JE. BioDrugs. 2017 Jun;31(3):263-274. doi: 10.1007/s40259-017-0217-6. BioDrugs. 2017. PMID: 28530020 Review.
Golimumab (Simponi()), a fully human monoclonal antibody against tumour necrosis factor-alpha (TNFalpha), is given once monthly by subcutaneous injection. ...Thus, golimumab is an effective, generally well tolerated and potentially convenient option for the treatmen …
Golimumab (Simponi()), a fully human monoclonal antibody against tumour necrosis factor-alpha (TNFalpha), is given once monthly by su …
Golimumab in inflammatory bowel diseases: present and future scenarios.
Dragoni G, Le Grazie M, Orlandini B, Rogai F. Dragoni G, et al. Clin J Gastroenterol. 2019 Feb;12(1):1-9. doi: 10.1007/s12328-018-0906-9. Epub 2018 Sep 11. Clin J Gastroenterol. 2019. PMID: 30206776 Review.
Golimumab is the third anti-TNF agent approved for the treatment of ulcerative colitis. ...Preliminary data also report golimumab efficacy in Crohn's disease with higher doses than in ulcerative colitis with an acceptable safety profile. ...
Golimumab is the third anti-TNF agent approved for the treatment of ulcerative colitis. ...Preliminary data also report golimumab …
Golimumab in the treatment of psoriatic arthritis.
Love TJ, Kavanaugh A. Love TJ, et al. Expert Rev Clin Immunol. 2018 Nov;14(11):893-898. doi: 10.1080/1744666X.2018.1524755. Epub 2018 Sep 27. Expert Rev Clin Immunol. 2018. PMID: 30221556 Review.
While many new agents have been approved for the treatment of PsA over the past decade, TNF inhibitors (TNFi)remain an anchor treatment, in part based on extensive clinical experience. Recently, the TNFi golimumab was approved for intravenous use in PsA. Areas covered: Thi …
While many new agents have been approved for the treatment of PsA over the past decade, TNF inhibitors (TNFi)remain an anchor treatment, in …
1,812 results